Pictet Asset Management’s Royalty Pharma RPRX Stock Holding History

Pictet Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.1M	Sell	303,466 -48,962	-14%	-$2.55M	0.02%	574
2026 Q1	$16.7M	Buy	352,428 +38,918	+12%	+$1.7M	0.02%	537
2025 Q4	$12.2M	Sell	313,510 -62,539	-17%	-$2.38M	0.01%	635
2025 Q3	$13.3M	Sell	376,049 -110,091	-23%	-$3.99M	0.01%	611
2025 Q2	$17.5M	Buy	486,140 +120,930	+33%	+$4.01M	0.02%	540
2025 Q1	$11.4M	Buy	365,210 +38,838	+12%	+$1.23M	0.01%	623
2024 Q4	$8.33M	Sell	326,372 -16,036	-5%	-$425K	0.01%	713
2024 Q3	$9.67M	Sell	342,408 -7,340	-2%	-$203K	0.01%	662
2024 Q2	$9.22M	Sell	349,748 -254,997	-42%	-$7.07M	0.01%	643
2024 Q1	$18.4M	Sell	604,745 -113,167	-16%	-$3.34M	0.02%	507
2023 Q4	$20.2M	Buy	717,912 +57,416	+9%	+$1.58M	0.02%	490
2023 Q3	$17.9M	Buy	+660,496	New	+$19.6M	0.02%	484

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pictet Asset Management's RPRX Position: Q2 2026 in Review

Pictet Asset Management reduced its Royalty Pharma (RPRX) stake by 14% in Q2 2026, selling an estimated $2.55M and leaving 303,466 shares worth $17.1M. The position accounts for 0.02% of the portfolio, ranked #574.

Pictet Asset Management first reported a position in RPRX in Q3 2023 and has held it in 12 quarters since. The position peaked at $20.2M in Q4 2023. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Pictet Asset Management held 303,466 shares of Royalty Pharma worth $17.1M as of Q2 2026.
Pictet Asset Management sold 48,962 Royalty Pharma shares in Q2 2026, an estimated $2.55M.
Royalty Pharma made up 0.02% of Pictet Asset Management's portfolio in Q2 2026, its #574 holding.
Pictet Asset Management first reported a position in Royalty Pharma in Q3 2023 and has held it in 12 quarters since.
Pictet Asset Management's Royalty Pharma position peaked at $20.2M in Q4 2023.
647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.